QUOTE AND NEWS
FiercePharma  May 17  Comment 
An ad campaign sponsored by Avanir featuring neurological condition PBA, characterized by inappropriate, uncontrolled outbursts of laughing or crying, has helped fuel the controversy over how DTC advertising takes niche medicine and promotes its...
FiercePharma  Dec 19  Comment 
Avanir shelves Danny Glover PBA awareness ad in favor of branded Nuedexta effort beth.bulik Mon, 12/19/2016 - 17:45
Benzinga  Jun 9  Comment 
Avanir Pharmaceuticals, Inc. today announced that the company will be presenting results from several studies about ONZETRA™ Xsail™ (sumatriptan nasal powder) 11 mg per nose piece, formerly AVP-825, at the 58th American Headache Society Annual...
newratings.com  May 16  Comment 
WASHINGTON (dpa-AFX) - Avanir Pharmaceuticals, Inc. (AVNR) announced ONZETRA Xsail or sumatriptan nasal powder is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration approved ONZETRA Xsail in January 2016...
FierceBiotech  Jan 22  Comment 
In this week's Chutes and Ladders, Rohan Palekar was appointed CEO of Avanir Pharmaceuticals, Allan Shaw was named CFO at Syndax, and Dr. Craig Granowitz was named chief medical officer at Amarin. Plus more hirings and retirings throughout the...
newratings.com  Jan 20  Comment 
WASHINGTON (dpa-AFX) - Avanir Pharmaceuticals, Inc. (AVNR) said it has appointed Rohan Palekar as its president and chief executive officer. He replaces Keith Katkin, who has served as president and CEO since March 2007 and will transition to the...
SeekingAlpha  Jan 20  Comment 
Benzinga  Sep 22  Comment 
Avanir Pharmaceuticals, Inc. today announced that results from a phase II study evaluating the efficacy and safety of AVP-923 for the treatment of agitation in patients with Alzheimer's disease were published today in the Journal of the American...





 
TOP CONTRIBUTORS
Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) is a biopharmaceutical company focused bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

The U.S. Food and Drug Administration (FDA) recently approved NUEDEXTA™ (dextromethorphan HBr and quinidine sulfate), for more information please visit www.nuedexta.com.

Avanir has conducted a Phase III study of AVP-923 in diabetic peripheral neuropathic (DPN) pain where the primary endpoints were successfully met.

Avanir has licensed macrophage migration inhibitory factor (MIF) program to Novartis International Pharmaceutical Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.



References

http://www.avanir.com/about/

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki